gage_trump

Trump to announce leaders of the US project to develop a coronavirus vaccine

pharmafile | May 14, 2020 | News story | Business Services COVID-19, Trump, Vaccine, coronavirus 

President Donald Trump is set to announce that Moncef Slaoui, the former head of GlaxoSmithKline’s vaccine division, and Gustave Perna, a four star US General, will lead a project to develop a coronavirus vaccine.

Known as ‘Operation Warp Speed’, Slaoui and Perna will work towards developing 300 million vaccines for the US. The project will utilise private pharmaceutical companies, government agencies and the military to try and develop a vaccine within the next 8 months, according to people familiar with the details who spoke to the press on the condition of anonymity.

The US is hoping to quicken the development of several different vaccine candidates and start production before clinical tests are complete. There has been recent controversy between the US and France, as French company Sanofi has said its first shipments of a COVID-19 vaccine would be sent to the US, because the American government is funding the vaccine.

During his time at GSK, Slaou oversaw vaccine pipelines that produced Rotarix, used to prevent diarrhea in infants, and Cervarix, used to protect against a viral infection that can lead to cervical cancer. He left the company in 2017 and joined the board of Moderna.

Perna has served as the Commander of the US Army Materiel Command, which manages the service’s supply chain across the world, since 2016. He was previously the Army’s deputy Chief of Staff.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

GSK shares new data for RSV vaccine Arexvy

GSK announced positive results from its phase 3 trial which assessed the immune response and …

Latest content